旺山旺水氢溴酸氘瑞米德韦干混悬剂启动三期临床 适应症为婴幼儿呼吸道合胞病毒感染

新浪财经
Feb 12

药物临床试验登记与信息公示平台数据显示,苏州旺山旺水生物医药有限公司、中国科学院上海药物研究所、中国科学院武汉病毒研究所的氢溴酸氘瑞米德韦干混悬剂一项在呼吸道合胞病毒感染的婴幼儿中评价氢溴酸氘瑞米德韦干混悬剂的有效性、安全性的随机、双盲、安慰剂对照III期临床试验已启动。临床试验登记号为CTR20260561,首次公示信息日期为2026年02月12日。该药物剂型为干混悬剂,用法用量为口服,每天给药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10